# EDGAR Filing Document

**Accession Number:** 0001454001
**File Stem:** 0000950103-25-007062
**Filing Date:** 2025-6
**Character Count:** 8644
**Document Hash:** 73f9309daa42f294decb9e60707a0d86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-007062.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0000950103-25-007062

**CONFORMED SUBMISSION TYPE**: 3/A

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20240102

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250605

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Squarer Ron
- **CENTRAL INDEX KEY:** 0001454001

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39071
- **FILM NUMBER:** 251027132

**MAIL ADDRESS:**
- **STREET 1:** C/O ADC THERAPEUTICS SA
- **STREET 2:** BIOPOLE, ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADC Therapeutics SA
- **CENTRAL INDEX KEY:** 0001771910
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
- **BUSINESS PHONE:** 41 21 653 02 00

**MAIL ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3/A

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Squarer Ron<br><sub>(Last) (First) (Middle)</sub><br>430 MOUNTAIN AVENUE<br>SUITE 404<br><sub>(Street)</sub><br>NEW PROVIDENCE, NJ 07974<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2024-01-02 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ADC Therapeutics SA [ ADCT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares |  |  |  |  |  |  |  | 35806<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | $18.75 |  |  |  |  |  |  | <sup>(2)</sup> | 2030-04-29 | Common Shares | 966519 |  |  | D |  |
| Stock Options (Right to Buy) | $28.70 |  |  |  |  |  |  | <sup>(3)</sup> | 2031-03-22 | Common Shares | 27412 |  |  | D |  |
| Stock Options (Right to Buy) | $14.00 |  |  |  |  |  |  | <sup>(4)</sup> | 2032-03-07 | Common Shares | 29836 |  |  | D |  |
| Stock Options (Right to Buy) | $18.75 |  |  |  |  |  |  | <sup>(5)</sup> | 2030-04-29 | Common Shares | 159026 |  |  | I | By grantor retained annuity trust |

---

### Footnotes:

(1) On January 2, 2024, a Form 3 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 2 of Table I by 11,852 shares due to an administrative error. This Form 3 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date and also applies to the number of shares reported as beneficially owned by the Reporting Person on any Forms 4 filed since January 2, 2024.

(2) On January 2, 2024, a Form 3 was filed on behalf of the Reporting Person which inadvertently underreported the number of securities reported in Column 3 of Table II by 468,977 shares due to an administrative error. This Form 3 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date and also applies to the number of shares reported as beneficially owned by the Reporting Person on any Forms 4 filed since January 2, 2024.

(3) On January 2, 2024, a Form 3 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 3 of Table II by 16,447 shares due to an administrative error. These options are fully vested and exercisable. This Form 3 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date and also applies to the number of shares reported as beneficially owned by the Reporting Person on any Forms 4 filed since January 2, 2024.

(4) On January 2, 2024, a Form 3 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 3 of Table II by 45,539 shares due to an administrative error. These options are fully vested and exercisable. This Form 3 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date and also applies to the number of shares reported as beneficially owned by the Reporting Person on any Forms 4 filed since January 2, 2024.

(5) Due to an administrative error, the previous Form 3 filing inadvertently overstated the number of options contributed to a grantor annuity trust for the benefit of the Ron Squarer 2014 Irrevocable Life Insurance Trust by 309,951 options. The correct number of options contributed to the grantor annuity trust for the benefit of the Ron Squarer 2014 Irrevocable Life Insurance Trust is reflected in this filing.

**Signature:** /s/ Ameet Mallik, as Attorney-in-Fact for Ron Squarer  
**Date:** 2025-06-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**